Subsequent Events	6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 - SUBSEQUENT EVENTS On July 14, 2023, the Company and UNION therapeutics A/S agreed to terminate the Research Collaboration and License Agreement dated August 12, 2020 entered into by the parties with regard to their proposed collaboration on the development and commercialization of certain Niclosamide-based drug products. Pursuant to the termination agreement, the Company has received back in full all rights previously granted to UNION with regard to a dry powder version of Niclosamide utilizing the Company’s TFF platform. The Company is presently evaluating its further development of a TFF dry powder version of Niclosamide. On August 14, 2023, the Company announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriter a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Subsequent Events

6 Months Ended

Jun. 30, 2023

NOTE 9 - SUBSEQUENT EVENTS

On July 14, 2023, the Company and UNION therapeutics A/S agreed to terminate the Research Collaboration and License Agreement dated August 12, 2020 entered into by the parties with regard to their proposed collaboration on the development and commercialization of certain Niclosamide-based drug products. Pursuant to the termination agreement, the Company has received back in full all rights previously granted to UNION with regard to a dry powder version of Niclosamide utilizing the Company’s TFF platform. The Company is presently evaluating its further development of a TFF dry powder version of Niclosamide.

On August 14, 2023, the Company announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriter a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.